These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34804076)

  • 1. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
    Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
    Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
    Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells for osteosarcoma.
    Tarek N; Lee DA
    Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
    Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
    Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cell Immunotherapy for Osteosarcoma.
    Tullius BP; Setty BA; Lee DA
    Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.
    Pahl JH; Ruslan SE; Kwappenberg KM; van Ostaijen-Ten Dam MM; van Tol MJ; Lankester AC; Schilham MW
    Cancer Immunol Immunother; 2013 Jul; 62(7):1235-47. PubMed ID: 23624801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
    Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
    Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.
    Merchant MS; Bernstein D; Amoako M; Baird K; Fleisher TA; Morre M; Steinberg SM; Sabatino M; Stroncek DF; Venkatasan AM; Wood BJ; Wright M; Zhang H; Mackall CL
    Clin Cancer Res; 2016 Jul; 22(13):3182-91. PubMed ID: 26823601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
    Buddingh EP; Schilham MW; Ruslan SE; Berghuis D; Szuhai K; Suurmond J; Taminiau AH; Gelderblom H; Egeler RM; Serra M; Hogendoorn PC; Lankester AC
    Cancer Immunol Immunother; 2011 Apr; 60(4):575-86. PubMed ID: 21240486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target.
    Zhu Y; Huang B; Shi J
    Oncotarget; 2016 Jul; 7(30):47163-47172. PubMed ID: 27323411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
    Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
    Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
    Vela M; Bueno D; González-Navarro P; Brito A; Fernández L; Escudero A; Valentín J; Mestre-Durán C; Arranz-Álvarez M; Pérez de Diego R; Mendiola M; Pozo-Kreilinger JJ; Pérez-Martínez A
    Front Immunol; 2019; 10():1814. PubMed ID: 31428099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
    Kimpo MS; Oh B; Lee S
    Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
    Kiany S; Gordon N
    Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
    Quamine AE; Olsen MR; Cho MM; Capitini CM
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity.
    Johann PD; Vaegler M; Gieseke F; Mang P; Armeanu-Ebinger S; Kluba T; Handgretinger R; Müller I
    BMC Cancer; 2010 Sep; 10():501. PubMed ID: 20858262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.